Page 1

camurus . INTERIM REPORT FOR THE FIRST QUARTER 2021 " Camurus had an excellent start of 2021 with strong revenue growth , new regulatory approvals and progress in the pipeline " TO Camurus is an international science - led biopharmaceutical company committed to developing and commercializing innovative medicines for the treatment of severe and chronic conditions . New drug products with best - in - class potential are conceived based on the unique proprietary FluidCrystal® drug delivery technologies and its extensive R & D and sales expertise . Camurus ' clinical pipeline includes product candidates for the treatment of cancer , endocrine diseases , pain and addiction , which are developed in - house and in collaboration with international pharmaceutical companies . Camurus ' share is listed on Nasdaq Stockholm under the ticker CAMX . For more information , visit camurus.com